obj groundhog day - tell me it isn't so!, page-18

Overseas money will not make itself visible in accumulation stage, that is a rule observed in plenty other shares I followed.

This all will change once accumulation gears into full swing buying.


If one checks the GSK website and the amount of innovative products being currently pursued, does one doubt that this relatively small elite club of biotechs being involved in this innovative push would not be individually followed by large investors close to GSK or familiar with its story?
We are talking about one of the three largest global pharma players.
Those remaining in the game after GSK's recent cleanup of
their research investments are most likely all multi baggers in the making.